计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 8 篇同行评审文献引用。
应用:
阿昔替尼已被用作血管内皮生长因子 (VEGF) 受体酪氨酸激酶抑制剂 (TKI) ,以研究其对肾癌细胞体外增殖的影响。 此外,在调理水 (CW) 中维持的脱氯胚胎中,它还用于抑制肠系膜上动脉 (AMA) 血管生成。
Information
Axitinib (AG 013736) is a multi-target inhibitor ofVEGFR1,VEGFR2,VEGFR3, PDGFRβ and c-Kit withIC50of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
In vitro
Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC).
In vivo
Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.
Cell Data
cell lines:DLBCL cells, SUDHL-6 cells
Concentrations:1 nM - 10 μM
Incubation Time:72 hours
Powder Purity:≥99%
| ALogP | 4.2 |
|---|